Artificial Intelligence and Drug Development from a patent perspective
Artificial intelligence (AI), like any other previous General Purpose Technology, is pervasive, improves over time and spans complementary innovations.
Artificial intelligence (AI), like any other previous General Purpose Technology, is pervasive, improves over time and spans complementary innovations.
This article is also available in French.
It has been a busy time for patent attorneys registered with the Unified Patent Court ("UPC"), totally overwhelmed by the large number of “opt-out” notifications filed.
The EPO's Enlarged Board of Appeal recently issued a G 2/21 "plausibility" decision regarding the possibility of taking into account experimental data submitted post-filing to support a technical e
The Unified Patent Court (UPC) Agreement signed in 2013 is a breakthrough for pan-European patent law.
On June 01, 2021, the fourth amendment of Patent Law in China entered into effect.
In a decision issued on November 21, 2023, the UK High Court overturned a previous ruling by the UK Patent Office, which had rejected a patent application (GB1904713.3), filed by Emotional Percepti
Xingye is a European Patent Attorney at the Amsterdam office of Plasseraud IP. Xingye has a Bachelor's degree in Chemistry and a PhD in Pharmacy and is fluent in Mandarin and English. Xingye started her career as a patent attorney in a leading UK private practice, where she was trained and qualified as both UK Chartered Patent Attorney and European Patent Attorney. She worked there for over 10 years with clients from the UK and abroad, mainly in the field of industrial chemistry, bioscience, pharmaceuticals, mechanical engineering, and polymer chemistry.